Content
Content
Team
Team
Companies
Companies
About
About
Products
Products
Signal
Brieflink
NFX Masterclass
Get our weekly newsletter that 321K+ startup teams read
Subscribe
Omri Amirav-Drory, Ph.D.
43
Focus Areas
All Focus Areas
Cybersecurity
· 4
Bio
· 35
Gaming
· 6
AI
· 47
PropTech
· 5
Space
· 6
Fintech
· 5
Marketplaces
· 26
Crypto
· 18
Silicon Valley
· 6
Israel
· 11
Europe
· 4
LatAm
· 4
By Author
Anna Piñol
Anastasia Budinskaya
Daniel Museles
Valerie Osband Mahoney
Morgan Beller
Omri Amirav-Drory, Ph.D.
Pete Flint
Gigi Levy-Weiss
James Currier
Topics
Network Effects
· 35
Fundraising
· 29
Growth
· 123
Leadership
· 57
Investment Memos
· 65
Psychology
· 54
Announcements
· 28
By Type
All NFX Content
· 435
Videos
· 38
Podcasts
· 90
Essays
· 173
Omri Amirav-Drory, Ph.D. · 43
Featured
The Next Industrial Revolution: Computational Biology & Bioplatforms
Featured
NFX Bio: Investing in Scientist-Founders from the Very Beginning with Omri Amirav-Drory
Featured
A Mammoth Becomes A Unicorn: Inside a Scientist-Founder’s Journey from Pre-Seed to Series D
Featured
Why C2i is the World’s First Platform for Cancer Intelligence
“Find a Way to Break Reality”: How Centivax Brought a Universal Flu Vaccine to Clinic
In Vitro, In Vivo, In China: How Early-Stage Companies Are Reaching the Clinic Faster Than Ever
Promoting Anastasia Budinskaya to Principal
The Founder’s Guide to JPM
Why NFX Invested in Cyclana Bio: A Bioplatform Building Physiologically Accurate Human Tissue Models
The AI Utopia Doesn’t Exist Without Bio
The Seasons of Fundraising
Women’s Health 2.0: Beyond Fertility
Longevity Can Save America
Why Don’t Billionaires Invest In Longevity?
Longevity’s First Blockbuster
The “Intangible” Game: How VCs See You
Why Great Bioplatforms Will Always Win
How to Start Your Own VC Fund
The Race to 160
Why NFX Invested in TwoStep Therapeutics: One Elegant Platform Targeting 90% of Cancers
How VCs Become Assholes
The Business Case for Longevity
A Scientific Approach To Your Company (And Your Life)
What I Wish I Knew as a Scientist-Founder
Featured
The Next Industrial Revolution: Computational Biology & Bioplatforms
Featured
NFX Bio: Investing in Scientist-Founders from the Very Beginning with Omri Amirav-Drory
Featured
A Mammoth Becomes A Unicorn: Inside a Scientist-Founder’s Journey from Pre-Seed to Series D
Featured
Why C2i is the World’s First Platform for Cancer Intelligence
“Find a Way to Break Reality”: How Centivax Brought a Universal Flu Vaccine to Clinic
In Vitro, In Vivo, In China: How Early-Stage Companies Are Reaching the Clinic Faster Than Ever
Promoting Anastasia Budinskaya to Principal
The Founder’s Guide to JPM
Why NFX Invested in Cyclana Bio: A Bioplatform Building Physiologically Accurate Human Tissue Models
The AI Utopia Doesn’t Exist Without Bio
The Seasons of Fundraising
Women’s Health 2.0: Beyond Fertility
Longevity Can Save America
Why Don’t Billionaires Invest In Longevity?
Longevity’s First Blockbuster
The “Intangible” Game: How VCs See You
Why Great Bioplatforms Will Always Win
How to Start Your Own VC Fund
The Race to 160
Why NFX Invested in TwoStep Therapeutics: One Elegant Platform Targeting 90% of Cancers
How VCs Become Assholes
The Business Case for Longevity
A Scientific Approach To Your Company (And Your Life)
What I Wish I Knew as a Scientist-Founder
Load More Content
Subscribe for more startup insights
Get our weekly newsletter that 321K+ startup teams read
Subscribe